- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL FOR CONDUCTING CHINA PHASE II CLINICAL TRIAL OF TT-00973 TABLETS IN COMBINATION WITH FIRMONERTINIB ... | 2 | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.07. | TransThera Completes Late-Stage Trial Enrollment For Bile Duct Cancer Drug | 3 | Benzinga.com | ||
| 02.07. | TRANSTHERA-B TT-01488 Tablets Combined With Anti-CD20 Monoclonal Antibody Regimen Approved for China Phase II Clinical Trial; Shares Surge 20% in Early Trading | 1 | AASTOCKS | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT ENROLLMENT COMPLETED IN THE GLOBAL MULTICENTER REGISTRATIONAL PHASE III CLINICAL TRIAL OF TINENGOTINIB MONOTHERAPY ... | 2 | HKEx | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL GRANTED FOR PHASE II CLINICAL TRIAL IN CHINA OF TT-01488 TABLETS IN COMBINATION WITH ANTI-CD20 MONOCLONAL ... | - | HKEx | ||
| 29.06. | TRANSTHERA-B Plans to Repurchase Up to RMB100M of H Shares | 1 | AASTOCKS | ||
| 23.06. | HSI Reverts Down 268 pts Midday; HSBC HOLDINGS Sets New High Against Mkt; BABA-W Loses 'Red-Chip' Status; TRANSTHERA-B Plunges 58% | 27 | AASTOCKS | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE STRATEGY COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2026; (2) CHANGE OF THE INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION ... | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 JUNE 2026; (2) ADOPTION OF THE H SHARE AWARD SCHEME; AND (3) AUTHORIZATION ... | 1 | HKEx | ||
| 12.06. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF OPERATING OFFICER | 1 | HKEx | ||
| 27.05. | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 27.05. | TRANSTHERA-B (02617): COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE | - | HKEx | ||
| 26.05. | TRANSTHERA-B (02617): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 18 JUNE 2026 AT 10:30 A.M. | - | HKEx |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,19 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,300 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,12 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 18,810 | -0,05 % | Erasca closes $632.5 million public stock offering | ||
| TARSUS PHARMACEUTICALS | 56,33 | +0,14 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,455 | +0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,310 | -0,08 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,765 | -0,03 % | BMO initiates Trevi Therapeutics stock at Outperform, $36 target | ||
| HEMAB THERAPEUTICS | 49,390 | 0,00 % | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | ||
| KYMERA THERAPEUTICS | 111,11 | +0,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 304,26 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| QIAGEN | 35,060 | -2,67 % | Evotec, Formycon oder Qiagen? Diese Aktie kann sich jetzt verdoppeln | Der europäische Biotech-Sektor bleibt in Bewegung: Unternehmensnachrichten, Partnerschaften und Analysteneinschätzungen sorgen derzeit für teils deutliche Kursausschläge. Bei Evotec, Formycon und Qiagen... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,800 | 0,00 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen | |
| VOR BIOPHARMA | 17,450 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,230 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |
Das Unternehmen TRANSTHERA SCIENCES NANJING INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +10,28 % bei einem Aktienkurs von 1,180 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.